10 results
8-K
EX-99.5
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
, if any, Kineta is able to generate from the sale of the product in that country. Adverse pricing limitations may hinder Kineta’s ability to recoup its
424B3
KA
Kineta Inc
10 Nov 22
Prospectus supplement
4:21pm
ability to recoup its investment in one or more product candidates, even if such product candidates obtain marketing approval.
Reimbursement
S-4
EX-10.16
c5nwg52gja6z3vmaiir
23 Sep 20
Registration of securities issued in business combination transactions
4:50pm
- Prev
- 1
- Next